{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:54:25Z","timestamp":1781632465939,"version":"3.54.5"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Unlike many other solid tumors, melanoma cells possess a remarkable ability to dynamically transition between distinct transcriptional states in response to environmental cues or therapeutic pressure. Among the adaptive mechanisms underlying this plasticity, the epithelial-to-mesenchymal transition (EMT) has garnered increasing attention, as it facilitates the shift from a proliferative, epithelial-like phenotype to a more invasive, mesenchymal-like phenotype frequently associated with cellular dormancy, quiescence and resistance to therapy. Despite growing interest in this phenomenon, the characterization of dormant cellular phenotypes and their clinical significance remains incomplete.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we adopted a comprehensive approach integrating patient-derived melanoma cell lines, bulk RNA sequencing from tumor biopsies and analysis of independent bulk and single-cell public datasets. This multi-dimensional strategy enabled the identification of a reproducible dichotomy between \u201cproliferative\u201d and \u201cdormant\u201d phenotypes, characterized by distinct levels of mitotic activity and mesenchymal gene expression profiles. By leveraging an eight-gene transcriptional signature, we constructed a \u201cdormancy score\u201d able to stratify tumors along a dormancy\u2013proliferation axis, revealing strong associations with clinical outcomes such as progression-free survival (PFS), overall survival (OS) and response to immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Within the dormant-associated gene module, the surface glycoprotein TACSTD2 (TROP2) emerged as a central hub gene. TROP2 expression was consistently upregulated in the dormant-like transcriptional state. Supporting these findings, single-cell RNA sequencing data confirmed that TROP2 marks a rare subpopulation of malignant cells that may constitute a quiescent, therapy-resistant niche. Besides, results highlight a predominant intracellular expression of TROP2 in the dormant phenotype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Together, these findings define a robust dormant phenotype in melanoma with both molecular and clinical significance and evaluate TROP2 as a potential biomarker and therapeutic target for identifying and eradicating dormant and treatment-refractory tumor cells.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03646-1","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T03:06:29Z","timestamp":1769569589000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biopsy RNA-seq captures TROP-2\u2013linked migration and clonal resistance to forecast aggressiveness in metastatic melanoma"],"prefix":"10.1186","volume":"45","author":[{"given":"Martina","family":"Betti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Accetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brindusa Ana Maria","family":"Arteni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anya","family":"Rosselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Melucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Visca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Botti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Pelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelangelo","family":"Russillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Ferraresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Migliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Cerro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Scalera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"De Nicola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Matteoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Covino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Guerrisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Pallocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Fanciulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Pescarmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Blandino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Italia","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Di Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"issue":"1","key":"3646_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"3646_CR2","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.3390\/cancers12102870","volume":"12","author":"I Falcone","year":"2020","unstructured":"Falcone I, Conciatori F, Bazzichetto C, Ferretti G, Cognetti F, Ciuffreda L, et al. Tumor microenvironment: implications in melanoma resistance to targeted therapy and immunotherapy. Cancers (Basel). 2020;12(10):2870.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"3646_CR3","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.3390\/ijms24044014","volume":"24","author":"E Ricciardi","year":"2023","unstructured":"Ricciardi E, Giordani E, Ziccheddu G, Falcone I, Giacomini P, Fanciulli M, et al. Metastatic melanoma: liquid biopsy as a new precision medicine approach. Int J Mol Sci. 2023;24(4):4014.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3646_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334.","journal-title":"N Engl J Med"},{"issue":"26","key":"3646_CR5","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521\u201332.","journal-title":"N Engl J Med"},{"issue":"1","key":"3646_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.det.2022.07.007","volume":"41","author":"J Lazaroff","year":"2023","unstructured":"Lazaroff J, Bolotin D. Targeted therapy and immunotherapy in melanoma. Dermatol Clin. 2023;41(1):65\u201377.","journal-title":"Dermatol Clin"},{"issue":"1","key":"3646_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and transcriptomic features of response to Anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165(1):35\u201344.","journal-title":"Cell"},{"issue":"7658","key":"3646_CR8","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature22794","volume":"546","author":"SM Shaffer","year":"2017","unstructured":"Shaffer SM, Dunagin MC, Torborg SR, Torre EA, Emert B, Krepler C, et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature. 2017;546(7658):431\u20135.","journal-title":"Nature"},{"issue":"4","key":"3646_CR9","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.cell.2018.06.025","volume":"174","author":"F Rambow","year":"2018","unstructured":"Rambow F, Rogiers A, Marin-Bejar O, Aibar S, Femel J, Dewaele M, et al. Toward minimal residual Disease-Directed therapy in melanoma. Cell. 2018;174(4):843\u201355. e19.","journal-title":"Cell"},{"issue":"8","key":"3646_CR10","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/s41556-020-0556-2","volume":"22","author":"NM Aiello-Couzo","year":"2020","unstructured":"Aiello-Couzo NM, Kang Y. A Bridge between melanoma cell States. Nat Cell Biol. 2020;22(8):913\u20134.","journal-title":"Nat Cell Biol"},{"issue":"7","key":"3646_CR11","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41568-019-0154-4","volume":"19","author":"I Arozarena","year":"2019","unstructured":"Arozarena I, Wellbrock C. Phenotype plasticity as enabler of melanoma progression and therapy resistance. Nat Rev Cancer. 2019;19(7):377\u201391.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"3646_CR12","doi-asserted-by":"publisher","first-page":"5761","DOI":"10.3390\/ijms22115761","volume":"22","author":"A Wessely","year":"2021","unstructured":"Wessely A, Steeb T, Berking C, Heppt MV. How neural crest transcription factors contribute to melanoma Heterogeneity, cellular Plasticity, and treatment resistance. Int J Mol Sci. 2021;22(11):5761.","journal-title":"Int J Mol Sci"},{"key":"3646_CR13","unstructured":"DeGeorgia SN, Kaufman CK. Specific SOX10 enhancer elements modulate phenotype plasticity and drug resistance in melanoma. BioRxiv. 2024."},{"issue":"5","key":"3646_CR14","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.ccell.2018.03.017","volume":"33","author":"J Tsoi","year":"2018","unstructured":"Tsoi J, Robert L, Paraiso K, Galvan C, Sheu KM, Lay J, et al. Multi-stage differentiation defines melanoma subtypes with differential vulnerability to Drug-Induced Iron-Dependent oxidative stress. Cancer Cell. 2018;33(5):890\u2013904. e5.","journal-title":"Cancer Cell"},{"issue":"5","key":"3646_CR15","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1111\/febs.16021","volume":"289","author":"D Pedri","year":"2022","unstructured":"Pedri D, Karras P, Landeloos E, Marine JC, Rambow F. Epithelial-to-mesenchymal-like transition events in melanoma. FEBS J. 2022;289(5):1352\u201368.","journal-title":"FEBS J"},{"issue":"2","key":"3646_CR16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.cpt.2024.07.002","volume":"3","author":"R Bangarh","year":"2025","unstructured":"Bangarh R, Saini RV, Saini AK, Singh T, Joshi H, Ramniwas S, et al. Dynamics of epithelial-mesenchymal plasticity driving cancer drug resistance. Cancer Pathog Ther. 2025;3(2):120\u20138.","journal-title":"Cancer Pathog Ther"},{"issue":"7420","key":"3646_CR17","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/nature11538","volume":"490","author":"J Landsberg","year":"2012","unstructured":"Landsberg J, Kohlmeyer J, Renn M, Bald T, Rogava M, Cron M, et al. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature. 2012;490(7420):412\u20136.","journal-title":"Nature"},{"key":"3646_CR18","doi-asserted-by":"publisher","first-page":"8755","DOI":"10.1038\/ncomms9755","volume":"6","author":"S Riesenberg","year":"2015","unstructured":"Riesenberg S, Groetchen A, Siddaway R, Bald T, Reinhardt J, Smorra D, et al. MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. Nat Commun. 2015;6:8755.","journal-title":"Nat Commun"},{"key":"3646_CR19","doi-asserted-by":"publisher","first-page":"5712","DOI":"10.1038\/ncomms6712","volume":"5","author":"J Muller","year":"2014","unstructured":"Muller J, Krijgsman O, Tsoi J, Robert L, Hugo W, Song C, et al. Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun. 2014;5:5712.","journal-title":"Nat Commun"},{"issue":"2","key":"3646_CR20","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.tips.2018.12.004","volume":"40","author":"A Recasens","year":"2019","unstructured":"Recasens A, Munoz L. Targeting cancer cell dormancy. Trends Pharmacol Sci. 2019;40(2):128\u201341.","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"3646_CR21","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","volume":"38","author":"PA Ewels","year":"2020","unstructured":"Ewels PA, Peltzer A, Fillinger S, Patel H, Alneberg J, Wilm A, et al. The nf-core framework for community-curated bioinformatics pipelines. Nat Biotechnol. 2020;38(3):276\u20138.","journal-title":"Nat Biotechnol"},{"issue":"12","key":"3646_CR22","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated Estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.","journal-title":"Genome Biol"},{"key":"3646_CR23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013;14:128.","journal-title":"BMC Bioinformatics"},{"issue":"7","key":"3646_CR24","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37(7):773\u201382.","journal-title":"Nat Biotechnol"},{"key":"3646_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","volume":"1711","author":"B Chen","year":"2018","unstructured":"Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243\u201359.","journal-title":"Methods Mol Biol"},{"key":"3646_CR26","unstructured":"Csardi GN. T. The Igraph software package for complex network Research. InterJournal 2006. Complex Syst, 1695. 2006."},{"issue":"4","key":"3646_CR27","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","volume":"175","author":"L Jerby-Arnon","year":"2018","unstructured":"Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint Blockade. Cell. 2018;175(4):984\u201397. e24.","journal-title":"Cell"},{"issue":"1","key":"3646_CR28","doi-asserted-by":"publisher","first-page":"5955","DOI":"10.1038\/s41467-021-25860-5","volume":"12","author":"SM Prakadan","year":"2021","unstructured":"Prakadan SM, Alvarez-Breckenridge CA, Markson SC, Kim AE, Klein RH, Nayyar N, et al. Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases. Nat Commun. 2021;12(1):5955.","journal-title":"Nat Commun"},{"issue":"6220","key":"3646_CR29","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhlen","year":"2015","unstructured":"Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.","journal-title":"Science"},{"issue":"1","key":"3646_CR30","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12964-025-02452-0","volume":"23","author":"A Simiczyjew","year":"2025","unstructured":"Simiczyjew A, Kot M, Majkowski M, Zietek M, Matkowski R, Nowak D. Phenotype switching in highly invasive resistant to Vemurafenib and Cobimetinib melanoma cells. Cell Commun Signal. 2025;23(1):449.","journal-title":"Cell Commun Signal"},{"issue":"11","key":"3646_CR31","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00432-025-06325-4","volume":"151","author":"L Sperber","year":"2025","unstructured":"Sperber L, von Brandenstein M, Kessler C, Heidenreich J, Storz E, Pfister D, et al. Expression and therapeutic potential of TROP2 in cisplatin-resistant germ cell tumors. J Cancer Res Clin Oncol. 2025;151(11):279.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"3646_CR32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s44318-024-00309-9","volume":"44","author":"A Aslemarz","year":"2025","unstructured":"Aslemarz A, Fagotto-Kaufmann M, Ruppel A, Fagotto-Kaufmann C, Balland M, Lasko P, et al. An EpCAM\/Trop2 mechanostat differentially regulates collective behaviour of human carcinoma cells. EMBO J. 2025;44(1):75\u2013106.","journal-title":"EMBO J"},{"issue":"1","key":"3646_CR33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12943-024-02104-w","volume":"23","author":"Y Sun","year":"2024","unstructured":"Sun Y, Yinwang E, Wang S, Wang Z, Wang F, Xue Y, et al. Phenotypic and Spatial heterogeneity of CD8(+) tumour infiltrating lymphocytes. Mol Cancer. 2024;23(1):193.","journal-title":"Mol Cancer"},{"issue":"4","key":"3646_CR34","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1158\/1078-0432.CCR-23-2566","volume":"30","author":"A Bessede","year":"2024","unstructured":"Bessede A, Peyraud F, Besse B, Cousin S, Cabart M, Chomy F, et al. TROP2 is associated with primary resistance to immune checkpoint Inhibition in patients with advanced Non-Small cell lung cancer. Clin Cancer Res. 2024;30(4):779\u201385.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3646_CR35","doi-asserted-by":"publisher","first-page":"1900508","DOI":"10.1080\/2162402X.2021.1900508","volume":"10","author":"NJJT Sl","year":"2021","unstructured":"Sl NJJT, Gt N. Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies. Oncoimmunology. 2021;10(1):1900508.","journal-title":"Oncoimmunology"},{"issue":"10","key":"3646_CR36","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1158\/0008-5472.CAN-12-3266","volume":"73","author":"M Trerotola","year":"2013","unstructured":"Trerotola M, Jernigan DL, Liu Q, Siddiqui J, Fatatis A, Languino LR. Trop-2 promotes prostate cancer metastasis by modulating beta(1) integrin functions. Cancer Res. 2013;73(10):3155\u201367.","journal-title":"Cancer Res"},{"key":"3646_CR37","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/1476-4598-9-253","volume":"9","author":"R Cubas","year":"2010","unstructured":"Cubas R, Zhang S, Li M, Chen C, Yao Q. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer. 2010;9:253.","journal-title":"Mol Cancer"},{"issue":"48","key":"3646_CR38","doi-asserted-by":"publisher","first-page":"28989","DOI":"10.18632\/oncotarget.25615","volume":"9","author":"DM Goldenberg","year":"2018","unstructured":"Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget. 2018;9(48):28989\u20139006.","journal-title":"Oncotarget"},{"issue":"2","key":"3646_CR39","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/onc.2012.36","volume":"32","author":"M Trerotola","year":"2013","unstructured":"Trerotola M, Cantanelli P, Guerra E, Tripaldi R, Aloisi AL, Bonasera V, et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene. 2013;32(2):222\u201333.","journal-title":"Oncogene"},{"key":"3646_CR40","doi-asserted-by":"publisher","first-page":"1332489","DOI":"10.3389\/fimmu.2023.1332489","volume":"14","author":"X Liu","year":"2023","unstructured":"Liu X, Li J, Deng J, Zhao J, Zhao G, Zhang T, et al. Targeting Trop2 in solid tumors: a look into structures and novel epitopes. Front Immunol. 2023;14:1332489.","journal-title":"Front Immunol"},{"issue":"2","key":"3646_CR41","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrm1835","volume":"7","author":"JP Thiery","year":"2006","unstructured":"Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131\u201342.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"3646_CR42","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/nrm3758","volume":"15","author":"S Lamouille","year":"2014","unstructured":"Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15(3):178\u201396.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"9","key":"3646_CR43","doi-asserted-by":"publisher","first-page":"166431","DOI":"10.1016\/j.bbadis.2022.166431","volume":"1868","author":"R Gundamaraju","year":"2022","unstructured":"Gundamaraju R, Lu W, Paul MK, Jha NK, Gupta PK, Ojha S, et al. Autophagy and EMT in cancer and metastasis: who controls whom? Biochim Biophys Acta Mol Basis Dis. 2022;1868(9):166431.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"2","key":"3646_CR44","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.3390\/ijms24021601","volume":"24","author":"SM Hossain","year":"2023","unstructured":"Hossain SM, Eccles MR. Phenotype switching and the melanoma Microenvironment; impact on immunotherapy and drug resistance. Int J Mol Sci. 2023;24(2):1601.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3646_CR45","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s10555-024-10172-z","volume":"43","author":"GR Bhat","year":"2024","unstructured":"Bhat GR, Sethi I, Sadida HQ, Rah B, Mir R, Algehainy N, et al. Cancer cell plasticity: from cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance. Cancer Metastasis Rev. 2024;43(1):197\u2013228.","journal-title":"Cancer Metastasis Rev"},{"issue":"19\u201320","key":"3646_CR46","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1101\/gad.329771.119","volume":"33","author":"F Rambow","year":"2019","unstructured":"Rambow F, Marine JC, Goding CR. Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities. Genes Dev. 2019;33(19\u201320):1295\u2013318.","journal-title":"Genes Dev"},{"issue":"18","key":"3646_CR47","doi-asserted-by":"publisher","first-page":"e108647","DOI":"10.15252\/embj.2021108647","volume":"40","author":"S Brabletz","year":"2021","unstructured":"Brabletz S, Schuhwerk H, Brabletz T, Stemmler MP. Dynamic EMT: a multi-tool for tumor progression. EMBO J. 2021;40(18):e108647.","journal-title":"EMBO J"},{"issue":"8","key":"3646_CR48","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.3390\/cancers12082154","volume":"12","author":"Y Tang","year":"2020","unstructured":"Tang Y, Durand S, Dalle S, Caramel J. EMT-Inducing transcription Factors, drivers of melanoma phenotype Switching, and resistance to treatment. Cancers (Basel). 2020;12(8):2154.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"3646_CR49","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3390\/biom15020269","volume":"15","author":"MK Zielinska","year":"2025","unstructured":"Zielinska MK, Ciazynska M, Sulejczak D, Rutkowski P, Czarnecka AM. Mechanisms of resistance to Anti-PD-1 immunotherapy in melanoma and strategies to overcome it. Biomolecules. 2025;15(2):269.","journal-title":"Biomolecules"},{"key":"3646_CR50","doi-asserted-by":"publisher","first-page":"873116","DOI":"10.3389\/fimmu.2022.873116","volume":"13","author":"V Benboubker","year":"2022","unstructured":"Benboubker V, Boivin F, Dalle S, Caramel J. Cancer cell phenotype plasticity as a driver of immune escape in melanoma. Front Immunol. 2022;13:873116.","journal-title":"Front Immunol"},{"issue":"8","key":"3646_CR51","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ccell.2021.05.015","volume":"39","author":"O Marin-Bejar","year":"2021","unstructured":"Marin-Bejar O, Rogiers A, Dewaele M, Femel J, Karras P, Pozniak J, et al. Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma. Cancer Cell. 2021;39(8):1135\u2013e498.","journal-title":"Cancer Cell"},{"issue":"3","key":"3646_CR52","doi-asserted-by":"publisher","first-page":"e1197","DOI":"10.1002\/ctm2.1197","volume":"13","author":"RP Patel","year":"2023","unstructured":"Patel RP, Somasundram PM, Smith LK, Sheppard KE, McArthur GA. The therapeutic potential of targeting minimal residual disease in melanoma. Clin Transl Med. 2023;13(3):e1197.","journal-title":"Clin Transl Med"},{"issue":"1","key":"3646_CR53","doi-asserted-by":"publisher","first-page":"BSR20211754","DOI":"10.1042\/BSR20211754","volume":"42","author":"P Debnath","year":"2022","unstructured":"Debnath P, Huirem RS, Dutta P, Palchaudhuri S. Epithelial-mesenchymal transition and its transcription factors. Biosci Rep. 2022;42(1):BSR20211754.","journal-title":"Biosci Rep"},{"issue":"4","key":"3646_CR54","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3390\/cancers14040916","volume":"14","author":"E Carrasco-Garcia","year":"2022","unstructured":"Carrasco-Garcia E, Lopez L, Moncho-Amor V, Carazo F, Aldaz P, Collado M, et al. SOX9 triggers different epithelial to mesenchymal transition States to promote pancreatic cancer progression. Cancers (Basel). 2022;14(4):916.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"3646_CR55","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12967-019-1895-2","volume":"17","author":"JQ Huang","year":"2019","unstructured":"Huang JQ, Wei FK, Xu XL, Ye SX, Song JW, Ding PK, et al. SOX9 drives the epithelial-mesenchymal transition in non-small-cell lung cancer through the Wnt\/beta-catenin pathway. J Transl Med. 2019;17(1):143.","journal-title":"J Transl Med"},{"issue":"7","key":"3646_CR56","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s00018-014-1791-0","volume":"72","author":"ML Hartman","year":"2015","unstructured":"Hartman ML, Czyz M. MITF in melanoma: mechanisms behind its expression and activity. Cell Mol Life Sci. 2015;72(7):1249\u201360.","journal-title":"Cell Mol Life Sci"},{"issue":"20","key":"3646_CR57","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1038\/s41388-024-03010-7","volume":"43","author":"S Durand","year":"2024","unstructured":"Durand S, Tang Y, Pommier RM, Benboubker V, Grimont M, Boivin F, et al. ZEB1 controls a lineage-specific transcriptional program essential for melanoma cell state transitions. Oncogene. 2024;43(20):1489\u2013505.","journal-title":"Oncogene"},{"key":"3646_CR58","doi-asserted-by":"crossref","unstructured":"Subhadarshini S, Sahoo S, Debnath S, Somarelli JA, Jolly MK. Dynamical modeling of proliferative-invasive plasticity and IFNgamma signaling in melanoma reveals mechanisms of PD-L1 expression heterogeneity. J Immunother Cancer. 2023;11(9):e0006766.","DOI":"10.1136\/jitc-2023-006766"},{"issue":"12","key":"3646_CR59","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.3390\/cancers15123147","volume":"15","author":"N Kharouf","year":"2023","unstructured":"Kharouf N, Flanagan TW, Hassan SY, Shalaby H, Khabaz M, Hassan SL, et al. Tumor microenvironment as a therapeutic target in melanoma treatment. Cancers (Basel). 2023;15(12):3147.","journal-title":"Cancers (Basel)"},{"key":"3646_CR60","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/B978-0-12-397927-8.00011-7","volume":"65","author":"R Somasundaram","year":"2012","unstructured":"Somasundaram R, Villanueva J, Herlyn M. Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations. Adv Pharmacol. 2012;65:335\u201359.","journal-title":"Adv Pharmacol"},{"issue":"1","key":"3646_CR61","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.1038\/s41598-022-09078-z","volume":"12","author":"M Nyakas","year":"2022","unstructured":"Nyakas M, Fleten KG, Haugen MH, Engedal N, Sveen C, Farstad IN, et al. AXL Inhibition improves BRAF-targeted treatment in melanoma. Sci Rep. 2022;12(1):5076.","journal-title":"Sci Rep"},{"key":"3646_CR62","doi-asserted-by":"publisher","first-page":"756001","DOI":"10.3389\/fonc.2021.756001","volume":"11","author":"F Huang","year":"2021","unstructured":"Huang F, Santinon F, Flores Gonzalez RE, Del Rincon SV. Melanoma plasticity: promoter of metastasis and resistance to therapy. Front Oncol. 2021;11:756001.","journal-title":"Front Oncol"},{"issue":"5","key":"3646_CR63","doi-asserted-by":"publisher","first-page":"105059","DOI":"10.1016\/j.esmoop.2025.105059","volume":"10","author":"J Wang","year":"2025","unstructured":"Wang J, Zhang Y, Bai R, Wu Y, Tong Z, Liu A, et al. Novel TROP2 antibody-drug conjugates for treatment of HER2-negative metastatic breast cancer patients with brain metastases: a promising option(\u2606). ESMO Open. 2025;10(5):105059.","journal-title":"ESMO Open"},{"issue":"3\u20134","key":"3646_CR64","first-page":"84","volume":"6","author":"A Shvartsur","year":"2015","unstructured":"Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical\/therapeutic implications. Genes Cancer. 2015;6(3\u20134):84\u2013105.","journal-title":"Genes Cancer"},{"issue":"1","key":"3646_CR65","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/ijms25010087","volume":"25","author":"T Koltai","year":"2023","unstructured":"Koltai T, Fliegel L. The relationship between Trop-2, chemotherapeutic Drugs, and chemoresistance. Int J Mol Sci. 2023;25(1):87.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3646_CR66","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.molonc.2016.09.009","volume":"11","author":"RR Gomis","year":"2017","unstructured":"Gomis RR, Gawrzak S. Tumor cell dormancy. Mol Oncol. 2017;11(1):62\u201378.","journal-title":"Mol Oncol"},{"issue":"1","key":"3646_CR67","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ccell.2023.12.011","volume":"42","author":"ET Goddard","year":"2024","unstructured":"Goddard ET, Linde MH, Srivastava S, Klug G, Shabaneh TB, Iannone S, et al. Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies. Cancer Cell. 2024;42(1):119\u201334. e12.","journal-title":"Cancer Cell"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03646-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03646-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03646-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:14:00Z","timestamp":1781630040000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03646-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3646"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03646-1","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"13 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Regina Elena National Cancer Institute IRCCS (Comitato Etico Centrale IRCCS Lazio-Sezione IRCCS I.F.O.\u2014Fondazione G.B. Bietti; protocol code 1441\/20, approved on 11 February 2021). All patients provided an informed consent that permitted testing and data collection, analysis and elaboration in an anonymous manner.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}